The pathological diagnoses were glioblastoma, IDH wild-type (n = 22, 27.5%), astrocytoma, IDH-mutant (n = 3, 3.8%), oligodendroglioma, IDH-mutant and 1p/19q codeleted (n = 1, 1.3%), diffuse midline glioma, H3K27-altered (n = 1, 1.3%), glioma not otherwise specified (NOS) (n = 11, 13.8%), primary central nervous system lymphoma (PCNSL; n = 27, 33.8%), germinoma (n = 1, 1.3%), myeloid sarcoma (n = 1, 1.3%), ganglioglioma (n = 1, 1.3%), subependymoma (n = 1, 1.3%), demyelinating lesion (n = 2, 2.5%), normal brain tissue/gliosis (n = 5, 6.3%), and undiagnosed (n = 4, 5.0%). This evidence concerns the gene IDH1 and myeloid sarcoma.